CA2591315C - Methode pour le traitement de la depression et des troubles d'humeur depressifs - Google Patents

Methode pour le traitement de la depression et des troubles d'humeur depressifs Download PDF

Info

Publication number
CA2591315C
CA2591315C CA2591315A CA2591315A CA2591315C CA 2591315 C CA2591315 C CA 2591315C CA 2591315 A CA2591315 A CA 2591315A CA 2591315 A CA2591315 A CA 2591315A CA 2591315 C CA2591315 C CA 2591315C
Authority
CA
Canada
Prior art keywords
day
serotonin
mao
depression
reserpine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2591315A
Other languages
English (en)
Other versions
CA2591315A1 (fr
Inventor
Elaine A. Delack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedDEV Inc
Original Assignee
MedDEV Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedDEV Inc filed Critical MedDEV Inc
Priority to CA2591315A priority Critical patent/CA2591315C/fr
Publication of CA2591315A1 publication Critical patent/CA2591315A1/fr
Application granted granted Critical
Publication of CA2591315C publication Critical patent/CA2591315C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une méthode pour le traitement de la dépression et des troubles dhumeur dépressive. Le patient reçoit une quantité dun composé qui accroît lactivité catalytique de la MAO-A, de façon à accroître le métabolisme synaptique de la sérotonine en 5-HIAL. Le composé efficace est de préférence de la réserpine, administrée à une dose inférieure à environ 0,03 mg par jour. La réserpine peut être administrée par voie transdermique à une dose située dans la plage denviron 0,002 mg par jour à environ 0,02 mg par jour. Un composé de caféine peut être administré simultanément de façon à compenser leffet antihypertenseur de la réserpine. Le composé de caféine peut être combiné à la réserpine dans une crème transdermique.
CA2591315A 2007-06-12 2007-06-12 Methode pour le traitement de la depression et des troubles d'humeur depressifs Expired - Fee Related CA2591315C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2591315A CA2591315C (fr) 2007-06-12 2007-06-12 Methode pour le traitement de la depression et des troubles d'humeur depressifs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2591315A CA2591315C (fr) 2007-06-12 2007-06-12 Methode pour le traitement de la depression et des troubles d'humeur depressifs

Publications (2)

Publication Number Publication Date
CA2591315A1 CA2591315A1 (fr) 2008-12-12
CA2591315C true CA2591315C (fr) 2014-11-04

Family

ID=40120361

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2591315A Expired - Fee Related CA2591315C (fr) 2007-06-12 2007-06-12 Methode pour le traitement de la depression et des troubles d'humeur depressifs

Country Status (1)

Country Link
CA (1) CA2591315C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112618556B (zh) * 2021-01-22 2022-03-25 上海中医药大学附属岳阳中西医结合医院 一种治郁用摩膏组方及其应用

Also Published As

Publication number Publication date
CA2591315A1 (fr) 2008-12-12

Similar Documents

Publication Publication Date Title
Beard et al. New pharmacological agents to aid smoking cessation and tobacco harm reduction: what has been investigated, and what is in the pipeline?
Tam et al. Yohimbine: a clinical review
Broadley The vascular effects of trace amines and amphetamines
Covey et al. Advances in non-nicotine pharmacotherapy for smoking cessation
US20020019421A1 (en) Compositions and therapy for substance addiction
US20080262053A1 (en) Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls)
US20110071102A1 (en) Compositions and Methods to Treat Recurrent Medical Conditions
Benowitz et al. Non-nicotine pharmacotherapy for smoking cessation: mechanisms and prospects
HUE035105T2 (en) A composition comprising nicotine and opipramole and its use
JP2003507420A (ja) 作用物質の組成物、クロニジンを含む前記組成物
US7737147B2 (en) Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
WO2006002096A2 (fr) Faibles doses de l-citrulline pour traiter des maladies
Kreisberg Tricyclic antidepressants: analgesic effect and indications in orofacial pain.
BG64888B1 (bg) Фармацевтични комбинации с трамадол
US7645766B1 (en) Method for treatment of depression and depressive mood disorders
Monti Primary and secondary insomnia: prevalence, causes and current therapeutics
CA2591315C (fr) Methode pour le traitement de la depression et des troubles d'humeur depressifs
AU2002360380B2 (en) Neurotransmitter balance chemotherapy
EP2022499B1 (fr) Traitement de dépression et des troubles de l'humeur dépressive
Aminoff Basic & Clinical Pharmacology
US20180055849A1 (en) Nutraceutical capsule and tablet formulations providing enhanced mental clarity, concentration and stamina while minimizing adrenaline and dopamine concentration perturbations associated with withdrawal
EP1347778B1 (fr) Chimiotherapie de comportement
Bloemen et al. Challenge and therapeutic studies using alpha-methyl-para-tyrosine (AMPT) in neuropsychiatric disorders: a review
AU2007202731A1 (en) Method for treatment of depression and depressive mood disorders
NZ555827A (en) Use of an rauwolfia alkaloid such as reserpine for treating depression and depressive mood disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210614